Evidence map›Paper›PMID 27346140›Full record

ArticleHPB : the official journal of the International Hepato Pancreato Biliary Association2016

Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC).

Neal Bhutiani, Prejesh Philips, Charles R Scoggins, Kelly M McMasters, Melissa H Potts, Robert C G Martin

Registry-linked trialAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in HPB : the official journal of the International Hepato Pancreato Biliary Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06045975 (Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure in Curative Intent), which is not on this map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06045975 phase2active not recruitingnot on this mapstarted 2024, after this paper: background citation

Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure in Curative Intent: French Multicenter Phase 2 Therapeutic

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2024 to 2028Enrolled30ConditionsHCC - Hepatocellular CarcinomaArmsDurvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Tissue Ablation: Applications and Perspectives.Advanced materials (Deerfield Beach, Fla.) · 2024
    Review
  9. New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Neal BhutianiUniversity of Louisville - Surgery, Division of Surgical Oncology, Louisville, KY, United States.
Prejesh PhilipsUniversity of Louisville - Surgery, Division of Surgical Oncology, Louisville, KY, United States.
Charles R ScogginsUniversity of Louisville - Surgery, Division of Surgical Oncology, Louisville, KY, United States.
Kelly M McMastersUniversity of Louisville - Surgery, Division of Surgical Oncology, Louisville, KY, United States.
Melissa H PottsUniversity of Louisville - Radiology, Louisville, KY 40202, United States.
Robert C G MartinUniversity of Louisville - Surgery, Division of Surgical Oncology, Louisville, KY, United States. Electronic address: Robert.Martin@louisville.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFew studies have assessed the tolerability and efficacy of irreversible electroporation (IRE) in the treatment of Child-Pugh B (7/8) patients with hepatocellular carcinoma (HCC). Based on its mechanism of action, we hypothesized that IRE would be superior to microwave (MW) ablation and compared the liver tolerance and ablation success rates of these therapies in Child-Pugh B patients with HCC.

methods55 patients with Child-Pugh B (7/8) HCC were treated with either MW ablation (n = 25) or IRE (n = 30). Tolerance and ablation success were evaluated at 30 and 90 days and 90 days and 6 months, respectively. Tolerance was defined as stable liver function and absence of increased ascites or worsening portal hypertension. Ablation success was defined as tumor eradication on triple phase contrasted computed tomography (CT).

resultsPatients undergoing IRE had shorter length of stay (p = 0.05) and 90 day readmission rate (p = 0.03) than those undergoing MW ablation. Additionally, IRE was better tolerated than MW ablation at 30 and 90 days. IRE and MW ablation resulted in 6 month success rates of 97% and 100%.

conclusionTreatment of Child-Pugh B (7/8) HCC with IRE results in equivalent ablation success with improved liver tolerance compared with MW ablation and other ablative modalities.

Indexed as

Ablation TechniquesElectroporationAgedAged, 80 and overCarcinoma, HepatocellularFemaleHumansLength of StayLiver NeoplasmsMaleMicrowavesMiddle AgedPatient ReadmissionPostoperative ComplicationsRegistriesRisk Factors

Identifiers

PMID27346140
PMCPMC4925804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.